TOLERANCE OF DOLUTEGRAVIR VERSUS RALTEGRAVIR COMBINED WITH TENOFOVIR DISOPROXIL AND EMTRICITABINE OR LAMIVUDINE AS POSTEXPOSURE PROPHYLAXIS AGAINST HIV INFECTION

Trial Profile

TOLERANCE OF DOLUTEGRAVIR VERSUS RALTEGRAVIR COMBINED WITH TENOFOVIR DISOPROXIL AND EMTRICITABINE OR LAMIVUDINE AS POSTEXPOSURE PROPHYLAXIS AGAINST HIV INFECTION

Planning
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2018

At a glance

  • Drugs Dolutegravir (Primary) ; Raltegravir (Primary) ; Emtricitabine; Lamivudine; Tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Adverse reactions
  • Acronyms DoRa
  • Most Recent Events

    • 21 Apr 2018 Status changed from not yet recruiting to planning.
    • 17 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top